Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders

Authors: Antonella Caivano, Ilaria Laurenzana, Luciana De Luca, Francesco La Rocca, Vittorio Simeon, Stefania Trino, Fiorella D’Auria, Antonio Traficante, Maddalena Maietti, Tiziana Izzo, Giovanni D’Arena, Giovanna Mansueto, Giuseppe Pietrantuono, Luca Laurenti, Pellegrino Musto, Luigi Del Vecchio

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Many cell types release extracellular vesicles (EVs), including exosomes, microvesicles (MVs), and apoptotic bodies, which play a role in physiology and diseases. Presence and phenotype of circulating EVs in hematological malignancies (HMs) remain largely unexplored.
The aim of this study was to characterize EVs in peripheral blood of HM patients compared to healthy subjects (controls). We isolated serum EVs from patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), Waldenstrom’s macroglobulinemia (WM), Hodgkin’s lymphoma (HL), multiple myeloma (MM), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), and controls. EVs were isolated from serum of peripheral blood by ultracentrifuge steps and analyzed by flow cytometry to define count, size, and immunophenotype. MV levels were significantly elevated in WM, HL, MM, AML, and some MPNs and, though at a lesser degree, in CLL and NHL as compared to healthy controls. HL, MM, and MPNs generated a population of MVs characterized by lower size (below 0.3 μm) when compared to controls. MVs from patients specifically expressed tumor-related antigens, such as CD19 in B cell neoplasms, CD38 in MM, CD13 in myeloid tumors, and CD30 in HL. Both total and antigen-specific count of MVs significantly correlated with different HM clinical features such as Rai stage in CLL, International Prognostic Scoring System in WM, International Staging System in MM, and clinical stage in HL. MVs may represent a novel biomarker in HMs.
Appendix
Available only for authorised users
Literature
1.
2.
El Andaloussi S, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347–57.CrossRef
3.
Zocco D, Ferruzzi P, Cappello F, Kuo WP. Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. Front Immunol. 2014;4:1–7.
4.
Julich H, Willms A, Lukacs-Kornek V. Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol. 2014;5:1–7.CrossRef
5.
Revenfeld ALS, Bæk R, Nielsen MH, Stensballe A, Varming K, Jørgensen M. Diagnostic and prognostic potential of extracellular vesicles in peripheral blood. Clin Ther. 2014;36(6):830–46.CrossRefPubMed
6.
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–89.CrossRefPubMed
7.
Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20(5):847–56.CrossRefPubMed
8.
Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011;26(5):1474–83.CrossRefPubMed
9.
Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183(3):1161–72.CrossRefPubMed
10.
Del Conde I. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5):1604–11.CrossRefPubMed
11.
Lee Y, EL Andaloussi S, Wood MJA. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1):R125–34.CrossRefPubMed
12.
Choi D-S, Kim D-K, Kim Y-K, Gho YS. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics. 2013;13(10–11):1554–71.CrossRefPubMed
13.
Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Nat Publ Group. 2014;24(6):766–9.
14.
15.
Caby MP. Exosomal-like vesicles are present in human blood plasma. Int Immunol. 2005;17(7):879–87.CrossRefPubMed
16.
Grant R, Ansa-Addo E, Stratton D, et al. A filtration-based protocol to isolate human plasma membrane-derived vesicles and exosomes from blood plasma. J Immunol Methods. 2011;371(1–2):143–51.CrossRefPubMed
17.
van der Meel R, Krawczyk-Durka M, van Solinge WW, Schiffelers RM. Toward routine detection of extracellular vesicles in clinical samples. Int J Lab Hematol. 2014;36(3):244–53.CrossRefPubMed
18.
Witwer KW, Buzás EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracellular Vesicles. 2013;2:18389.CrossRef
19.
Dinkla S, Brock R, Joosten I, Bosman GJCGM. Gateway to understanding microparticles: standardized isolation and identification of plasma membrane-derived vesicles. Nanomedicine (Lond). 2013;8(10):1657–68.CrossRef
20.
Shet AS. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102(7):2678–83.CrossRefPubMed
21.
Jayachandran M, Litwiller RD, Owen WG, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008;295(3):H931–8.CrossRefPubMedPubMedCentral
22.
George JN, Thoi LL, McManus LM, Reimann TA. Isolation of human platelet membrane microparticles from plasma and serum. Blood. 1982;60(4):834–40.PubMed
23.
van der Vlist EJ, Nolte-‘t Hoen ENM, Stoorvogel W, Arkesteijn GJA, Wauben MHM. Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. Nat Protoc. 2012;7(7):1311–26.CrossRefPubMed
24.
Lacroix R, Robert S, Poncelet P, et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC collaborative workshop. J Thromb Haemost. 2010;8(11):2571–4.CrossRefPubMed
25.
Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost. 2012;10(3):437–46.CrossRefPubMed
26.
Van Der Pol E, Van Gemert M, Sturk A, Nieuwland R, Van Leeuwen T. Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost. 2012;10(5):919–30.
27.
Connor DE, Exner T, Ma DDF, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost. 2010;103(5):1044–52.CrossRefPubMed
28.
Rooney IA, Atkinson JP, Krul ES, et al. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med. 1993;177(5):1409–20.CrossRefPubMed
29.
Clayton A, Harris CL, Court J, Mason MD, Morgan BP. Antigen‐presenting cell exosomes are protected from complement‐mediated lysis by expression of CD55 and CD59. Eur J Immunol. 2003;33(2):522–31.CrossRefPubMed
30.
Gyorgy B, Modos K, Pallinger E, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood. 2011;117(4):e39–48.CrossRefPubMed
31.
György B, Pálóczi K, Kovács A, et al. Improved circulating microparticle analysis in acid-citrate dextrose (ACD) anticoagulant tube. Thromb Res. 2014;133(2):285–92.CrossRefPubMed
32.
Fleitas T, Martínez-Sales V, Vila V, et al. Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS ONE. 2012;7(10):e47365.CrossRefPubMedPubMedCentral
33.
Nozaki T, Sugiyama S, Sugamura K, et al. Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail. 2014;12(11):1223–8.CrossRef
34.
Schmelzle M, Splith K, Andersen LW, et al. Increased plasma levels of microparticles expressing CD39 and CD133 in acute liver injury. Transplant J. 2013;95(1):63–9.CrossRef
35.
Sinning JM, Losch J, Walenta K, Bohm M, Nickenig G, Werner N. Circulating CD31+/annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J. 2011;32(16):2034–41.CrossRefPubMed
36.
Dragovic RA, Southcombe JH, Tannetta DS, Redman CWG, Sargent IL. Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women. Biol Reprod. 2013;89(6):151.CrossRefPubMed
37.
Van Aalderen M, Trappenburg M, Van Schilfgaarde M, et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost. 2011;9(1):223–6.CrossRefPubMed
38.
Ayers L, Kohler M, Harrison P, et al. Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res. 2011;127(4):370–7.CrossRefPubMed
39.
Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115(9):1755–64.CrossRefPubMedPubMedCentral
40.
Auwerda JJA, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105(1):14–20.CrossRefPubMed
41.
Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-1. Haematologica. 2011;96(9):1302–9.CrossRefPubMedPubMedCentral
42.
Dey-Hazra E, Hertel B, Kirsch T, et al. Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. VHRM. 2010;6:1125–33.
43.
Jy W, Horstman LL, Jimenez JJ, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2(10):1842–51.CrossRefPubMed
44.
Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109(4):175–80.CrossRefPubMed
45.
Abid Hussein MN, Meesters EW, Osmanovic N, Romijn FPHTM, Nieuwland R, Sturk A. Antigenic characterization of endothelial cell‐derived microparticles and their detection ex vivo. J Thromb Haemost. 2003;1(11):2434–43.CrossRefPubMed
46.
Berardi S, Caivano A, Ria R, et al. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene. 2012;31(18):2258–69.CrossRefPubMed
47.
Terpos E, Tasidou A, Kastritis E, et al. Angiogenesis in waldenstrãm's macroglobulinemia. Clin Lymphoma Myeloma. 2011;9(1):46–9.CrossRef
48.
Marinaccio C, Nico B, Maiorano E, Specchia G, Ribatti D. Insights in hodgkin lymphoma angiogenesis. Leuk Res. 2014;38(8):857–61.CrossRefPubMed
49.
Cooper LJN, Al-Kadhimi Z, DiGiusto D, et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cell Mol Dis. 2004;33(1):83–9.CrossRef
50.
Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/waldenström macroglobulinemia. Am J Clin Pathol. 2005;124(3):414–20.CrossRefPubMed
51.
Paiva B, Montes MC, a-Sanz RGI, et al. Multiparameter flow cytometry for the identification of the waldenstrom's clone in IgM-MGUS and waldenström macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia. 2013;28(1):166–73.CrossRefPubMed
52.
Domnikova NP, Dolgikh TY, Sholenberg EV, et al. Blood microvesicles during chronic lymphoproliferative diseases. Bull Exp Biol Med. 2013;156(1):94–7.CrossRefPubMed
53.
Nijhof IS, Groen RWJ, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802–10.CrossRefPubMed
54.
Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014;5(14):5686–99.CrossRefPubMedPubMedCentral
55.
56.
Hansen HP, Engels H-M, Dams M, et al. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma. J Pathol. 2014;232(4):405–14.CrossRefPubMed
57.
Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome. Blood. 1998;91(8):3011–6.PubMed
58.
Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448–58.CrossRefPubMed
59.
Dahle J, Repetto-Llamazares AHV, Mollatt CS, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin’s lymphoma. Anticancer Res. 2013;33(1):85–95.PubMed
60.
Oksvold MP, Kullmann A, Forfang L, et al. Expression of B-Cell surface antigens in subpopulations of exosomes released from B-Cell lymphoma cells. Clin Ther. 2014;36(6):847–862.e1.CrossRefPubMed
Metadata
Title
High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders
Authors
Antonella Caivano
Ilaria Laurenzana
Luciana De Luca
Francesco La Rocca
Vittorio Simeon
Stefania Trino
Fiorella D’Auria
Antonio Traficante
Maddalena Maietti
Tiziana Izzo
Giovanni D’Arena
Giovanna Mansueto
Giuseppe Pietrantuono
Luca Laurenti
Pellegrino Musto
Luigi Del Vecchio
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3741-3

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma

Research Article

Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin

Research Article

Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression

Research Article

Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord

Research Article

Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma

Research Article

Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits